The first new drug to be launched simultaneously in China and the United States is expected to be born

On March 10, Wuxi Pharmaceutical Co., Ltd and Lilly, an American pharmaceutical giant, announced in Shanghai that they would jointly develop, produce and commercialize a new small molecule oral lipid-lowering drug This lipid-lowering drug is expected to become the first new drug in China and the United States The new small molecule lipid-lowering drug jointly developed by Wuxi apptec and Lilly is an oral preparation once a day, aiming to reduce the risk of cardiovascular disease in the high-risk population related to low-density lipoprotein cholesterol and triglyceride elevation Wuxi apptec will be responsible for the development, production and registration of the drug in China, including the submission of new drug clinical trial applications Lilly will be responsible for the marketing of the drug in China According to Gao Xin, vice president of Shanghai Zhongshan Hospital, the originality of this small molecule lipid-lowering drug is to reduce the risk of hypertriglyceridemia into the treatment target Before that, most of the general lipid-lowering drugs only used LDL-C as an index to measure the risk of cardiovascular disease This originality will improve the therapeutic effect on cardiovascular patients with diabetes at the same time According to the World Health Organization, in 2012, ischemic heart disease and stroke were the first and second leading causes of death in the world Data shows that the number of cardiovascular disease patients in China has reached 290 million Andrew Hodge, President of Lilly pharmaceutical China, said at the conference that the research and development of the lipid-lowering drug is in phase I, and toxicity research has been completed in the United States, and clinical research will be carried out at the same time in China and the United States "China has a wide range of patients with high cholesterol, which lays a good foundation for the next clinical research, so the clinical trial of the drug is expected to be completed in China first, and we also look forward to China becoming the first country in the world to register and approve the new drug." He said Mu Hua, senior vice president of Wuxi apptec, told reporters that China has become the second largest pharmaceutical market in the world, but for a long time, China has been unable to meet the people's demand for new drugs by relying on its own innovation It is difficult for domestic patients to use the latest global innovative drugs simultaneously with foreign patients The cooperation between Wuxi apptec and Lilly is just to break this bottleneck, introduce international high-level drugs into China, carry out simultaneous development and marketing, and bring biomedical technology representing global level into China at the fastest speed Yang Qing, chief operating officer of Wuxi apptec, said the strategic cooperation with Lilly is the first time that Chinese pharmaceutical companies have established in-depth partnership with us pharmaceutical giants in drug research and development This is a replicable and popularized model In the future, Wuxi apptec will have deeper and less extensive cooperation with Lilly, and will actively seek other strategic partners In February this year, the State Food and Drug Administration announced a series of measures to reform the drug review and approval system, including that "applications for registration of innovative drugs that are not marketed or transferred to production in China or abroad will be reviewed and approved preferentially" Industry insiders predict that, driven by this policy, more innovative drugs will emerge in China in the future, which will be listed simultaneously with the international market.